新医学2024，Vol.55Issue(1)：30-34,5.DOI:10.3969/j.issn.0253-9802.2024.01.006
他莫昔芬治疗包裹性腹膜硬化症的研究进展
Research progress in tamoxifen in treatment of encapsulating peritoneal sclerosis
摘要
Abstract
Encapsulating peritoneal sclerosis(EPS)is a rare and serious complication in patients with long-term peritoneal dialysis and a history of recurrent and severe peritoneal dialysis-associated peritonitis(PDAP).Early diagnosis of EPS is difficult,clinical prognosis is poor,and the fatality rate is high.The pathogenesis of EPS is still not fully understood,and ideal prevention and treatment regimens are still lacking.Tamoxifen,a selective estrogen receptor modulator,is currently used in the treatment of breast cancer,ovarian cancer and some diseases characterized by fibrotic lesions.Studies have shown that tamoxifen can also be used to treat EPS.In this article,research progress in EPS and tamoxifen in the treatment of EPS was systematically reviewed.关键词
他莫昔芬/包裹性腹膜硬化症/选择性雌激素受体调节剂/腹膜透析/治疗Key words
Tamoxifen/Encapsulating peritoneal sclerosis/Selective estrogen receptor modulators/Peritoneal dialysis/Therapy引用本文复制引用
康达贤,孙丽萍,张欣洲..他莫昔芬治疗包裹性腹膜硬化症的研究进展[J].新医学,2024,55(1):30-34,5.基金项目
广东省高水平临床重点专科基金(深圳市配套建设经费)(SZGSP001) （深圳市配套建设经费）
深圳市科技创新委员会可持续发展专项(KCXFZ20201221173612034) （KCXFZ20201221173612034）
